Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease

[1]  R. Bazan,et al.  Enzyme replacement therapy for Anderson-Fabry disease. , 2016, The Cochrane database of systematic reviews.

[2]  C. Hollak,et al.  A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance , 2013, Journal of Medical Genetics.

[3]  G. A. van der Marel,et al.  Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. , 2013, Clinical chemistry.

[4]  C. Hollak,et al.  Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine , 2012, Hypertension.

[5]  A. Moens,et al.  Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. , 2012, American journal of physiology. Endocrinology and metabolism.

[6]  J. Shayman,et al.  Glycosphingolipid Mediated Caveolin-1 Oligomerization. , 2012, Journal of glycomics & lipidomics.

[7]  S. Pennathur,et al.  Quantitative analysis of amino Acid oxidation markers by tandem mass spectrometry. , 2011, Methods in enzymology.

[8]  C. Hollak,et al.  Vasculopathy in patients with Fabry disease: current controversies and research directions. , 2010, Molecular genetics and metabolism.

[9]  This work is licensed under a Creative Commons Attribution-NonCommercial- NoDerivs 3.0 Licence. To view a copy of the licence please see: http://creativecommons.0rg/licenses/by-nc-nd/3.0/ INEQIMTES IN THE DELIVERY OF SERVICES TO A FEMALE FARM CLIENTELE: SOME~~ , 2010 .

[10]  James L. Park,et al.  Decreased nitric oxide bioavailability in a mouse model of Fabry disease. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  R. Schiffmann,et al.  Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. , 2008, Molecular genetics and metabolism.

[12]  James L. Park,et al.  VASCULAR DYSFUNCTION IN THE α‐GALACTOSIDASE A‐KNOCKOUT MOUSE IS AN ENDOTHELIAL CELL‐, PLASMA MEMBRANE‐BASED DEFECT , 2008, Clinical and experimental pharmacology & physiology.

[13]  R. Brady,et al.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.

[14]  J. Shayman,et al.  Caveolin-associated Accumulation of Globotriaosylceramide in the Vascular Endothelium of α-Galactosidase A Null Mice* , 2007, Journal of Biological Chemistry.

[15]  J. Charrow,et al.  Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. , 2007, Journal of the American Society of Nephrology : JASN.

[16]  C. R. Bagnell,et al.  Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926 , 1990, In Vitro Cellular & Developmental Biology.

[17]  J. Viikari,et al.  Structural and functional changes in peripheral vasculature of Fabry patients , 2006, Journal of Inherited Metabolic Disease.

[18]  J. Shayman,et al.  An in vitro model of Fabry disease. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  S. Novo,et al.  Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease. , 2005, International angiology : a journal of the International Union of Angiology.

[20]  O. Raitakari,et al.  Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease , 2005, Journal of Inherited Metabolic Disease.

[21]  A. Undas,et al.  Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography , 2005, Cardiovascular ultrasound.

[22]  J. Shayman,et al.  &agr;-Galactosidase A Deficiency Accelerates Atherosclerosis in Mice With Apolipoprotein E Deficiency , 2005, Circulation.

[23]  A. Chait,et al.  Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.

[24]  R. Desnick,et al.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. , 2004, American journal of human genetics.

[25]  M. Brys,et al.  Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease , 2004, Journal of Neurology.

[26]  B. Stemper,et al.  Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease , 2003, Journal of Neurology.

[27]  S. Hazen,et al.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.

[28]  A. Abe,et al.  Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. , 2003, Journal of the American Society of Nephrology : JASN.

[29]  J. Heinecke.  Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. , 2002, Free radical biology & medicine.

[30]  P. Shaul.  Regulation of endothelial nitric oxide synthase: location, location, location. , 2002, Annual review of physiology.

[31]  R. Schiffmann,et al.  Elevated Cerebral Blood Flow Velocities in Fabry Disease With Reversal After Enzyme Replacement , 2002, Stroke.

[32]  R. Schiffmann,et al.  Enhanced Endothelium-Dependent Vasodilation in Fabry Disease , 2001, Stroke.

[33]  H. Ischiropoulos.  Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.

[34]  C. Edgell,et al.  Permanent cell line expressing human factor VIII-related antigen established by hybridization. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Y. Seino,et al.  Peripheral hemodynamics in patients with Fabry's disease. , 1983, American heart journal.

[36]  J. Scheerer,et al.  Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[37]  J. Kint.  Fabry's Disease: Alpha-Galactosidase Deficiency , 1970, Science.

[38]  R. Brady,et al.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. , 1967, The New England journal of medicine.

[39]  C. Duve,et al.  Functions of lysosomes. , 1966, Annual review of physiology.

[40]  W. F. Lever,et al.  Angiokeratoma Corporis Diffusum (FABRY): Histochemical and Electron Microscopic Studies of the Skin* , 1965 .

[41]  C. Sweeley,et al.  FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID. , 1963, The Journal of biological chemistry.